Hereditary angioedema due to C1 - inhibitor deficiency in Switzerland: clinical characteristics and therapeutic modalities within a cohort study

Table 7 Prophylaxis with danazol and comparison of location-related symptoms between women and men in 2012

Location of attacks	All	Women			no prophylaxis vs. Danazol	Men			no prophylaxis vs. Danazol	women vs. men
Location of attacks	All	All	No prophylaxis	Danazol	p-values	All	No prophylaxis	Danazol	p-values	p-values
	104	57	31	13		47	28	13
abdomen	68 (65 %)	40 (70 %)	24 (77 %)	6 (46 %)	p = 0.042	28 (59 %)	15 (53 %)	9 (69 %)	p = 0.344	p = 0.063
extremities	61 (59 %)	34 (60 %)	20 (64 %)	5 (38 %)	p = 0.111	27 (57 %)	14 (50 %)	8 (61 %)	p = 0.491	p = 0.157
trunk	22 (21 %)	15 (26 %)	8 (26 %)	3 (10 %)	p = 0.849*	7 (15 %)	4 (14 %)	0	p = 0.288*	p = 0.523*
face	22 (21 %)	14 (24 %)	8 (26 %)	2 (6 %)	p = 0.697*	8 (17 %)	4 (14 %)	1 (8 %)	p = 0.486**	p = 0.709**
genitals	22 (21 %)	11 (19 %)	8 (26 %)	1 (3 %)	p = 0.242*	11 (23 %)	5 (18 %)	3 (23 %)	p = 0.692*	p = 0.586*
headache	16 (15 %)	11 (19 %)	4 (13 %)	3 (10 %)	p = 0.404*	5 (11 %)	4 (14 %)	0	p = 0.288*	p = 0.509*
larynx	16 (15 %)	9 (16 %)	6 (19 %)	1 (3 %)	p = 0.654	7 (15 %)	4 (14 %)	1 (8 %)	p = 0.486**	p = 0.700**

* Fisher’s exact test, ** one-sided
Number of patients who suffered from at least one attack in the individual location in 2012

ISSN: 1750-1172